Evidence map›Paper›PMID 41160242›Full record

ReviewWorld journal of microbiology & biotechnology2025

Yeast Midas' touch: recent advances in the valorisation of methanol by yeasts.

Alessandra Mauri, Lorenzo García Tejada, Lars M Blank

Erratum issuedAbstract readReview
In one paragraph

Review in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Alessandra MauriInstitute of Applied Microbiology (iAMB), RWTH Aachen University, Aachen, Germany.
Lorenzo García TejadaInstitute of Applied Microbiology (iAMB), RWTH Aachen University, Aachen, Germany.
Lars M BlankInstitute of Applied Microbiology (iAMB), RWTH Aachen University, Aachen, Germany. lars.blank@rwth-aachen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditionally, methanol has been used as a building block for a plethora of applications. It holds a key role in the chemical industry to produce paints, fabric, solvents, and plastics, and in producing biodiesel as the alcohol counterpart in the transesterification of plant oils and animal fats. Recently, methanol regained attention in industrial biotechnology due to its potential as an alternative substrate. Specifically, methanol is natively metabolised by a group of microorganisms called methylotrophs. Endowed with peculiar physiology, these can utilise the reduced C1 molecule as their sole caglycerol can derepress the methanol oxidase promoterrbon and energy source. While efforts to implement methylotrophic metabolism in heterologous hosts are still in its infancy, genetic engineering of methylotrophic yeast already succeeded in the conversion of methanol into high-value compounds, such as organic acids or recombinant proteins, boosting their potential as cell factories. Moreover, current technology developments allow for methanol synthesis from biomass or CO

Indexed as

MethanolYeastsAlcohol OxidoreductasesBiofuelsBiomassBiotechnologyGenetic EngineeringIndustrial MicrobiologyMetabolic Engineeringalcohol oxidaseAlcohol OxidoreductasesBiofuelsMethanolBioeconomyC1 metabolismIndustrial bioprocessingLand-free biotechnologyMethanolMethylotrophic yeast

Identifiers

PMID41160242
PMCPMC12572079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.